ProstACT Global Study: Status
Telix today provides an update to confirm the current status of the ProstACT Global Phase 3 study of its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosopatamab tetraxetan) in…
Read moreNews & Views
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
News,
Telix today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinical applications that combine Telix’s theranostic products and…
Read more
ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed
News,
Telix today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate…
Read more
Telix at SUO 2025
Join Telix at the 2025 Society of Urologic Oncology (SUO) Annual Meeting, one of the world’s leading international congresses dedicated to advances in urologic cancer care. Telix will be showcasing…
Read more
Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held
News,
Telix today announces the official opening of Telix Manufacturing Solutions (TMS) in Yokohama, Japan, the Company’s first cyclotron facility in the Asia Pacific region…
Read more
ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
Telix today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®[1], 89Zr-DFO-girentuximab) PET/CT[2] would have undergone a change in clinical management,…
Read more
OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer
Telix today announces that final positive results from the Phase 2 OPALESCENCE trial[1] of TLX250-CDx (89Zr-girentuximab) in metastatic triple negative breast cancer (mTNBC) have been published in the European Journal…
Read more
TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging
Telix today welcomes updated guidelines from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM) and The American College of Nuclear Medicine (ACNM)…
Read more
Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain
Telix today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153Samarium (Sm)-DOTMP), a therapeutic radiopharmaceutical candidate for treating pain associated with bone…
Read more
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
Telix today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated…
Read more